Ameriprise
FLGT icon

Ameriprise’s Fulgent Genetics FLGT Stock Holding History

Ameriprise’s Portfolio FLGT Stock Details FLGT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$8.96M Buy
563,375
+63,864
+13% +$1.39M ﹤0.01% 2005
2025
Q4 		$13.1M Buy
499,511
+4,558
+0.9% +$118K ﹤0.01% 1712
2025
Q3 		$11.2M Sell
494,953
-3,442
-0.7% -$70.9K ﹤0.01% 1834
2025
Q2 		$9.91M Sell
498,395
-126,908
-20% -$2.47M ﹤0.01% 1832
2025
Q1 		$10.6M Buy
625,303
+123,494
+25% +$2.1M ﹤0.01% 1723
2024
Q4 		$9.27M Buy
501,809
+145,518
+41% +$2.84M ﹤0.01% 1862
2024
Q3 		$7.74M Buy
356,291
+1,566
+0.4% +$35K ﹤0.01% 2026
2024
Q2 		$6.96M Sell
354,725
-5,410
-2% -$113K ﹤0.01% 2041
2024
Q1 		$7.81M Buy
360,135
+109,514
+44% +$2.72M ﹤0.01% 2011
2023
Q4 		$7.25M Buy
250,621
+184,263
+278% +$4.93M ﹤0.01% 2057
2023
Q3 		$1.77M Sell
66,358
-6,017
-8% -$205K ﹤0.01% 2874
2023
Q2 		$2.68M Sell
72,375
-4,420
-6% -$154K ﹤0.01% 2733
2023
Q1 		$2.4M Sell
76,795
-1,861
-2% -$59.9K ﹤0.01% 2754
2022
Q4 		$2.34M Sell
78,656
-7,845
-9% -$281K ﹤0.01% 2738
2022
Q3 		$3.3M Sell
86,501
-11,755
-12% -$589K ﹤0.01% 2519
2022
Q2 		$5.36M Sell
98,256
-336
-0.3% -$18.5K ﹤0.01% 2224
2022
Q1 		$6.15M Sell
98,592
-10,511
-10% -$692K ﹤0.01% 2280
2021
Q4 		$11M Sell
109,103
-24,390
-18% -$2.14M ﹤0.01% 1915
2021
Q3 		$12M Buy
133,493
+35,181
+36% +$3.2M ﹤0.01% 1704
2021
Q2 		$9.02M Buy
98,312
+2,550
+3% +$204K ﹤0.01% 2019
2021
Q1 		$9.25M Buy
95,762
+32,296
+51% +$3.33M ﹤0.01% 1942
2020
Q4 		$3.31M Buy
63,466
+10,701
+20% +$447K ﹤0.01% 2535
2020
Q3 		$2.11M Sell
52,765
-45,170
-46% -$1.41M ﹤0.01% 2633
2020
Q2 		$1.57M Sell
97,935
-29,490
-23% -$452K ﹤0.01% 2721
2020
Q1 		$1.37M Buy
+127,425
New +$1.77M ﹤0.01% 2673

Other funds holding FLGT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
ICM
Invenomic Capital Management Boston, Massachusetts $2.18B AUM 0.03% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Ameriprise's FLGT Position: Q1 2026 in Review

Ameriprise increased its Fulgent Genetics (FLGT) stake by 13% in Q1 2026, buying an estimated $1.39M and bringing the position to 563,375 shares worth $8.96M. The position accounts for ﹤0.01% of the portfolio, ranked #2005.

Ameriprise first reported a position in FLGT in Q1 2020 and has held it in 25 quarters since. The position peaked at $13.1M in Q4 2025. 157 funds tracked by Wall St. Rank hold FLGT as of Q1 2026.

  • Ameriprise held 563,375 shares of Fulgent Genetics worth $8.96M as of Q1 2026.
  • Ameriprise bought 63,864 Fulgent Genetics shares in Q1 2026, an estimated $1.39M.
  • Fulgent Genetics made up ﹤0.01% of Ameriprise's portfolio in Q1 2026, its #2005 holding.
  • Ameriprise first reported a position in Fulgent Genetics in Q1 2020 and has held it in 25 quarters since.
  • Ameriprise's Fulgent Genetics position peaked at $13.1M in Q4 2025.
  • 157 funds tracked by Wall St. Rank held Fulgent Genetics as of Q1 2026.

Based on Ameriprise's 13F filing for Q1 2026, filed 15 May 2026.